New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
- Molecular Response
- 10865 Road to the Cure
- San Diego CA, 92121
- UNITED STATES
Molecular Response is an oncology-focused CRO, with a viable primary tumor bank of more than 140,000 clinical biopsies, spanning 76 diagnoses. Tumors are employed to create Patient-Derived Xenograft (PDX) models, 3D cell culture for ex-vivo pharmacology studies, and genomic surveys for target prevalence. Tumors have histology/pathology reports, ex-vivo drug resistance data and matched FFPE blocks. These platforms allow for in vivo and ex-vivo drug candidate selection, patient stratification, biomarker verification, and development of Companion Diagnostic assays in CAP/CLIA-accredited labs.